$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000082787122000027 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q4
Revenue	$60.70M	$65.90M	$42.32M
YoY Change	43.43%	65.36%	-15.22%
Cost Of Revenue	$19.87M	$20.87M	$12.31M
YoY Change	61.39%	280.4%	-1.84%
Gross Profit	$40.83M	$45.03M	$30.01M
YoY Change	36.06%	31.03%	-19.71%
Gross Profit Margin	67.27%	68.33%	70.91%
Selling, General & Admin	$24.15M	$23.46M	$20.33M
YoY Change	18.82%	26.95%	11.74%
% of Gross Profit	59.14%	52.1%	67.73%
Research & Development	$7.217M	$9.326M	$3.787M
YoY Change	90.57%	-59.96%	-59.71%
% of Gross Profit	17.67%	20.71%	12.62%
Depreciation & Amortization	$5.630M	$200.0K	$1.067M
YoY Change	427.65%	1.52%	21.25%
% of Gross Profit	13.79%	0.44%	3.56%
Operating Expenses	$31.37M	$32.79M	$24.11M
YoY Change	30.09%	-21.51%	-12.57%
Operating Profit	$9.466M	$9.462M	$5.899M
YoY Change	60.47%	-192.97%	-39.81%
Interest Expense	-$1.663M	$1.147M	-$4.530M
YoY Change	-63.29%	189.65%	1061.54%
% of Operating Profit	-17.57%	12.12%	-76.79%
Other Income/Expense, Net	$5.501M	-$13.13M	-$145.0K
YoY Change	-3893.79%	428.59%	-107.29%
Pretax Income	$13.30M	-$3.663M	$1.224M
YoY Change	986.93%	-71.07%	-89.25%
Income Tax	$5.139M	$3.468M	$7.420M
% Of Pretax Income	38.63%		606.21%
Net Earnings	$8.165M	-$7.131M	-$6.196M
YoY Change	-231.78%	26.84%	-176.87%
Net Earnings / Revenue	13.45%	-10.82%	-14.64%
Basic Earnings Per Share		-$0.54
Diluted Earnings Per Share	$0.62	-$0.54	-$480.5K
COMMON SHARES
Basic Shares Outstanding	13.02M shares	13.17M shares	12.91M shares
Diluted Shares Outstanding		13.17M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$55.32M	$15.38M	$103.0M
YoY Change	-46.28%	-85.25%	-0.18%
Cash & Equivalents	$55.32M	$15.38M	$97.66M
Short-Term Investments	$0.00	$0.00	$5.312M
Other Short-Term Assets	$13.20M	$2.165M	$3.159M
YoY Change	317.85%	-10.83%	96.82%
Inventory	$47.79M	$63.86M	$21.91M
Prepaid Expenses
Receivables	$72.44M	$96.93M	$41.15M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$188.8M	$185.0M	$172.6M
YoY Change	9.36%	7.78%	3.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.168M	$1.297M	$1.636M
YoY Change	-28.61%	-26.93%	-21.23%
Goodwill	$45.03M	$41.79M	$39.74M
YoY Change	13.31%	5.16%	0.0%
Intangibles	$118.3M	$108.8M	$10.67M
YoY Change	1008.87%	907.36%	-17.39%
Long-Term Investments
YoY Change
Other Assets	$52.88M	$25.99M	$10.28M
YoY Change	414.48%	78.76%	-40.27%
Total Long-Term Assets	$217.4M	$201.4M	$81.13M
YoY Change	167.99%	138.16%	-6.89%
TOTAL ASSETS
Total Short-Term Assets	$188.8M	$185.0M	$172.6M
Total Long-Term Assets	$217.4M	$201.4M	$81.13M
Total Assets	$406.2M	$386.4M	$253.7M
YoY Change	60.07%	50.8%	0.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.99M	$13.22M	$16.43M
YoY Change	15.59%	3.92%	162.14%
Accrued Expenses	$85.84M	$73.65M	$32.34M
YoY Change	165.46%	165.76%	35.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.250M	$35.00M	$25.61M
YoY Change	-75.59%	337.5%	220.09%
Total Short-Term Liabilities	$111.1M	$121.8M	$74.38M
YoY Change	49.36%	151.55%	95.29%
LONG-TERM LIABILITIES
Long-Term Debt	$56.22M	$26.43M	$0.00
YoY Change		35.62%	-100.0%
Other Long-Term Liabilities	$5.297M	$1.874M	$2.903M
YoY Change	82.47%	-38.52%	-26.67%
Total Long-Term Liabilities	$61.51M	$28.31M	$2.903M
YoY Change	2018.95%	25.59%	-90.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$111.1M	$121.8M	$74.38M
Total Long-Term Liabilities	$61.51M	$28.31M	$2.903M
Total Liabilities	$172.6M	$154.7M	$77.28M
YoY Change	123.35%	117.94%	15.03%
SHAREHOLDERS EQUITY
Retained Earnings	$111.5M	$103.3M	$75.86M
YoY Change	46.98%	25.93%	-10.21%
Common Stock	$18.00K	$18.00K	$17.00K
YoY Change	5.88%	5.88%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$243.1M	$243.1M	$225.1M
YoY Change	8.0%	12.31%	10.4%
Treasury Stock Shares	4.553M shares	4.553M shares	4.112M shares
Shareholders Equity	$233.6M	$231.8M	$176.5M
YoY Change
Total Liabilities & Shareholders Equity	$406.2M	$386.4M	$253.7M
YoY Change	60.07%	50.8%	0.21%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	$8.165M	-$7.131M	-$6.196M
YoY Change	-231.78%	26.84%	-176.87%
Depreciation, Depletion And Amortization	$5.630M	$200.0K	$1.067M
YoY Change	427.65%	1.52%	21.25%
Cash From Operating Activities	$37.56M	-$13.24M	$8.081M
YoY Change	364.76%	-1340.58%	-59.1%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$0.00	-$49.00K
YoY Change	-120.41%	-100.0%	-71.18%
Acquisitions
YoY Change
Other Investing Activities	$1.000K	-$11.24M	$0.00
YoY Change
Cash From Investing Activities	-$9.000K	-$11.24M	-$49.00K
YoY Change	-81.63%	224640.0%	-71.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.389M	3.296M	-10.11M
YoY Change	-123.62%	-132.84%	65.26%
NET CHANGE
Cash From Operating Activities	37.56M	-13.24M	8.081M
Cash From Investing Activities	-9.000K	-11.24M	-49.00K
Cash From Financing Activities	2.389M	3.296M	-10.11M
Net Change In Cash	39.94M	-21.18M	-2.082M
YoY Change	-2018.2%	135.94%	-115.46%
FREE CASH FLOW
Cash From Operating Activities	$37.56M	-$13.24M	$8.081M
Capital Expenditures	$10.00K	$0.00	-$49.00K
Free Cash Flow	$37.55M	-$13.24M	$8.130M
YoY Change	361.83%	-1334.79%	-59.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36306
	dei	Entity Registrant Name EntityRegistrantName	Eagle Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8179278
	dei	Entity Address Address Line1 EntityAddressAddressLine1	50 Tice Boulevard
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 315
	dei	Entity Address City Or Town EntityAddressCityOrTown	Woodcliff Lake
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07677
	dei	City Area Code CityAreaCode	(201)
	dei	Local Phone Number LocalPhoneNumber	326-5300
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	EGRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13015856	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15384000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97659000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	96932000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41149000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	63855000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	21908000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8875000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11890000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	185046000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	172606000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1636000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	108785000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10671000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	41794000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	39743000	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	23541000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	18798000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25986000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10278000	usd
CY2022Q3	us-gaap	Assets Assets	386449000	usd
CY2021Q4	us-gaap	Assets Assets	253732000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	13215000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16431000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73652000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32338000	usd
CY2022Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	34961000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	25607000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	121828000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	74376000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	26431000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4536000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1874000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2903000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	154669000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	77279000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17568586	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16903034	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	18000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000	usd
	us-gaap	Royalty Expense RoyaltyExpense	8036000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	362161000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	325779000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9377000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-94000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	103339000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	75862000	usd
CY2022Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	4552730	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	4111622	shares
CY2022Q3	us-gaap	Treasury Stock Value TreasuryStockValue	243115000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	225111000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	231780000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	176453000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	386449000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	253732000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	65901000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39853000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	255911000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	129226000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	20869000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5486000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	67216000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21835000	usd
CY2022Q3	us-gaap	Royalty Expense RoyaltyExpense	2782000	usd
CY2021Q3	us-gaap	Royalty Expense RoyaltyExpense	2773000	usd
	us-gaap	Royalty Expense RoyaltyExpense	7854000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9326000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23289000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26871000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47488000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23462000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18482000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	82476000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	54997000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	56439000	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	50030000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	184417000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	132356000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	9462000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10177000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	71494000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3130000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	-444000	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	197000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	-46000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	395000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1147000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	396000	usd
	us-gaap	Interest Expense InterestExpense	2065000	usd
	us-gaap	Interest Expense InterestExpense	1240000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11534000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2284000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21254000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1797000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13125000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2483000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23365000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2642000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3663000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12660000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	48129000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5772000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3468000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7038000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20652000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3341000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7131000	usd
	us-gaap	Net Income Loss NetIncomeLoss	27477000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2431000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13166931	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13077298	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12906235	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13103203	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13166931	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13077298	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13051311	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13103203	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7131000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5622000	usd
	us-gaap	Net Income Loss NetIncomeLoss	27477000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2431000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-510000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	22000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	94000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-882000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	7606000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	9377000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7096000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	22000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9471000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-882000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5600000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	36948000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3313000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	237982000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3537000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	247000	usd
CY2022Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	9951000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7096000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7131000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	231780000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	194847000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4084000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	233000	usd
CY2021Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	8271000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	22000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5622000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	185293000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	176453000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12332000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1747000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	23645000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-1341000	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	18004000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9471000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9471000	usd
	us-gaap	Net Income Loss NetIncomeLoss	27477000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	231780000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	186011000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14873000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1841000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-1551000	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	12568000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-882000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2431000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	185293000	usd
	us-gaap	Net Income Loss NetIncomeLoss	27477000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2431000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-4743000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2533000	usd
	us-gaap	Depreciation Depreciation	508000	usd
	us-gaap	Depreciation Depreciation	575000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	917000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	768000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5886000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2118000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-3208000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1900000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	12332000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	14873000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	354000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	354000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-962000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	254000	usd
	egrx	Accretion Income AccretionIncome	0	usd
	egrx	Accretion Income AccretionIncome	102000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7309000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4444000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-150000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55325000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5343000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15006000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1240000	usd
	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	831000	usd
	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	8821000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3824000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6449000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	33888000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3897000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	4412000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	908000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13144000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20138000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	74153000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	12500000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	168000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	274000	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	5000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86821000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5274000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1747000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1841000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	15000000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1341000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1551000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6000000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	18004000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	12568000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8598000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18278000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-82275000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3414000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97659000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103155000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15384000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99741000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	18855000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6303000	usd
	us-gaap	Interest Paid Net InterestPaidNet	894000	usd
	us-gaap	Interest Paid Net InterestPaidNet	917000	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation and Other Company Information <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2021 was derived from audited financial statements, but certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results for the year ending December 31, 2022 or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 8, 2022. </span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an integrated pharmaceutical company focused on finding ways to help medicines do more for patients. We and our collaborators have the capabilities to take a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. Our business model applies our scientific expertise, proprietary research-based insights and marketplace proficiency to identify challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. By focusing on patients' unmet needs, we strive to provide healthcare professionals with urgently needed treatment solutions that are designed to improve patient care and outcomes and create near- and long-term value for our stakeholders, including patients and healthcare providers and our employees, marketing partners, collaborators and investors. Our science-based business model has a proven track record with the U.S. Food and Drug Administration ("FDA") approval and commercial launches of six products: PEMFEXY® (pemetrexed for injection), vasopressin, an A-rated generic alternative to Vasostrict®, Ryanodex® (dantrolene sodium) ("Ryanodex"), bendamustine ready-to-dilute ("RTD") 500ml solution ("Belrapzo"), and rapidly infused bendamustine RTD ("Bendeka") and RTD (“Treakisym”). We market our products through marketing partners and/or our internal direct sales force. We market PEMFEXY, vasopressin, Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. ("Teva") markets Bendeka through its subsidiary Cephalon, Inc. SymBio Pharmaceuticals Limited ("SymBio"), markets Treakisym, a RTD product, in Japan.</span></div>On June 9, 2022, we acquired all of the outstanding share capital of Acacia Pharma Group plc (“Acacia”), which added two FDA approved new chemical entities with patent protection, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection). Refer to Note 14 for further details.
	egrx	Number Of Products Launched NumberOfProductsLaunched	6	product
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These condensed consolidated financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements including disclosure of gross to net estimates as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and also require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertai</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n. We anticipate that the COVID-19 pandemic will continue to disrupt our supply chain and marketing and sales efforts for certain of our products, although it is not currently expected that any disruption would be significant. As of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the condensed consolidated financial statements, actual results may materially vary from these estimates, and any such differences may be material to our condensed consolidated financial statements.</span></div>
CY2022Q3	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	8125000	usd
CY2022Q3	us-gaap	Fair Value Liabilities Measured On Recurring Basis Obligations FairValueLiabilitiesMeasuredOnRecurringBasisObligations	4063000	usd
CY2021Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	57357000	usd
CY2021Q4	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	4021000	usd
CY2021Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Asset EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset	962000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	6030000	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12500000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1700000	usd
CY2021Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	500000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	5100000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1300000	usd
CY2022Q3	egrx	Revenue From Contract With Customer Wholesaler Discount RevenueFromContractWithCustomerWholesalerDiscount	0.02
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5622000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7131000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7131000	usd
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2869493	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2446657	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2784799	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2901595	shares
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5622000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	27477000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	27477000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2431000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2431000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13166931	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13077298	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12906235	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13103203	shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	145076	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13166931	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13077298	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13051311	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13103203	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7760000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7591000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6463000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5955000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1636000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	9704000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7317000	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	21246000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9666000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	32905000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4925000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	63855000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	21908000	usd
CY2022Q3	us-gaap	Prepaid Taxes PrepaidTaxes	566000	usd
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1173000	usd
CY2022Q3	egrx	Prepaid Fda User Fee And Advances To Clinical Research Organizations PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations	0	usd
CY2021Q4	egrx	Prepaid Fda User Fee And Advances To Clinical Research Organizations PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations	1108000	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	537000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	196000	usd
CY2022Q3	egrx	Advances To Commercial Manufacturers AdvancesToCommercialManufacturers	3164000	usd
CY2021Q4	egrx	Advances To Commercial Manufacturers AdvancesToCommercialManufacturers	2354000	usd
CY2022Q3	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	1445000	usd
CY2021Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	0	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	5312000	usd
CY2022Q3	egrx	Other Receivables Cost Sharing Arrangement With Commercial Partner OtherReceivablesCostSharingArrangementWithCommercialPartner	998000	usd
CY2021Q4	egrx	Other Receivables Cost Sharing Arrangement With Commercial Partner OtherReceivablesCostSharingArrangementWithCommercialPartner	347000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2165000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1400000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8875000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11890000	usd
CY2022Q3	egrx	Accrued Product Sales Reserves Current AccruedProductSalesReservesCurrent	21662000	usd
CY2021Q4	egrx	Accrued Product Sales Reserves Current AccruedProductSalesReservesCurrent	4390000	usd
CY2022Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5750000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2022Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	9724000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5085000	usd
CY2022Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3702000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8466000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7622000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2013000	usd
CY2022Q3	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	4233000	usd
CY2021Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	4100000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1508000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1309000	usd
CY2022Q3	egrx	Inventory Received But Not Invoiced InventoryReceivedButNotInvoiced	14431000	usd
CY2021Q4	egrx	Inventory Received But Not Invoiced InventoryReceivedButNotInvoiced	6177000	usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4063000	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	957000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	798000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73652000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32338000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y3M18D
CY2022Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
	us-gaap	Operating Lease Cost OperatingLeaseCost	1173000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1407000	usd
	us-gaap	Lease Cost LeaseCost	1173000	usd
CY2021	us-gaap	Lease Cost LeaseCost	1407000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1173000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1407000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	270000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1508000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1874000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3382000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	119750000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10965000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	108785000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23850000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13179000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10671000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3700000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5900000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3690000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	14405000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	14127000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	13886000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	11584000	usd
CY2022Q3	egrx	Finite Lived Intangible Assets Expected Amortization After Year Four FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour	51093000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	108785000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3331890	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	109000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100477	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	308815	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3031598	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2814878	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	123700	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	91255	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	73983	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2773340	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0147
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0366
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0051
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0112
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4683
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5607
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M3D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M4D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3537000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4084000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12332000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14873000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3537000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4084000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12332000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14873000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3621000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	414000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1672000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1122000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	413000	usd
CY2022Q3	egrx	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	0	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	59324000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	35000000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	4257000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	12162000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	7905000	usd
CY2022Q3	egrx	Long Term Debt Maturity After Year Three LongTermDebtMaturityAfterYearThree	0	usd
CY2022Q3	us-gaap	Contractual Obligation ContractualObligation	12500000	usd
CY2022Q3	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	0	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12500000	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	0	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	0	usd
CY2022Q3	egrx	Contractual Obligation To Be Paid After Year Three ContractualObligationToBePaidAfterYearThree	0	usd
CY2022Q3	us-gaap	Purchase Obligation PurchaseObligation	99403000	usd
CY2022Q3	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	99403000	usd
CY2022Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	0	usd
CY2022Q3	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	usd
CY2022Q3	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	usd
CY2022Q3	egrx	Purchase Obligation To Be Paid After Year Three PurchaseObligationToBePaidAfterYearThree	0	usd
CY2022Q3	egrx	Obligation Obligation	174848000	usd
CY2022Q3	egrx	Obligation To Be Paid Remainder Of Fiscal Year ObligationToBePaidRemainderOfFiscalYear	134817000	usd
CY2022Q3	egrx	Obligation To Be Paid Year One ObligationToBePaidYearOne	18429000	usd
CY2022Q3	egrx	Obligation To Be Paid Year Two ObligationToBePaidYearTwo	13284000	usd
CY2022Q3	egrx	Obligation To Be Paid Year Three ObligationToBePaidYearThree	8318000	usd
CY2022Q3	egrx	Obligation To Be Paid After Year Three ObligationToBePaidAfterYearThree	0	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	400000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1200000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1000000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3600000	usd
CY2022Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	100000	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12500000	usd
CY2022Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	35000000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	35000000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	4257000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	12162000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	7905000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	59324000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3468000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7038000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20652000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3341000	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.95
CY2021Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.56
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.43
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.58
	egrx	Number Of Tax Jurisdictions Currently Auditing The Company NumberOfTaxJurisdictionsCurrentlyAuditingTheCompany	3	jurisdiction
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q3	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	1300000	usd
CY2022Q2	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	-3300000	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12500000	usd

Files In Submission

Name	View Source	Status
0000827871-22-000027-index-headers.html	Edgar Link	pending
0000827871-22-000027-index.html	Edgar Link	pending
0000827871-22-000027.txt	Edgar Link	pending
0000827871-22-000027-xbrl.zip	Edgar Link	pending
egrx-20220930.htm	Edgar Link	pending
egrx-20220930.xsd	Edgar Link	pending
exhibit104hospirasettlemen.htm	Edgar Link	pending
exhibit311q320221.htm	Edgar Link	pending
exhibit312q320221.htm	Edgar Link	pending
exhibit321q320221.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
image_10a.jpg	Edgar Link	pending
image_12a.jpg	Edgar Link	pending
image_13a.jpg	Edgar Link	pending
image_14a.jpg	Edgar Link	pending
image_15a.jpg	Edgar Link	pending
image_16a.jpg	Edgar Link	pending
image_17a.jpg	Edgar Link	pending
image_18a.jpg	Edgar Link	pending
image_19a.jpg	Edgar Link	pending
image_1a.jpg	Edgar Link	pending
image_20a.jpg	Edgar Link	pending
image_21a.jpg	Edgar Link	pending
image_22a.jpg	Edgar Link	pending
image_23a.jpg	Edgar Link	pending
image_24a.jpg	Edgar Link	pending
image_25a.jpg	Edgar Link	pending
image_26a.jpg	Edgar Link	pending
image_27a.jpg	Edgar Link	pending
image_28a.jpg	Edgar Link	pending
image_29a.jpg	Edgar Link	pending
image_30a.jpg	Edgar Link	pending
image_31a.jpg	Edgar Link	pending
image_32a.jpg	Edgar Link	pending
image_33a.jpg	Edgar Link	pending
image_34a.jpg	Edgar Link	pending
image_35a.jpg	Edgar Link	pending
image_36a.jpg	Edgar Link	pending
egrx-20220930_def.xml	Edgar Link	unprocessable
egrx-20220930_lab.xml	Edgar Link	unprocessable
egrx-20220930_cal.xml	Edgar Link	unprocessable
egrx-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
egrx-20220930_htm.xml	Edgar Link	completed
image_37a.jpg	Edgar Link	pending
image_38a.jpg	Edgar Link	pending
image_39a.jpg	Edgar Link	pending
image_3a.jpg	Edgar Link	pending
image_40a.jpg	Edgar Link	pending
image_41a.jpg	Edgar Link	pending
image_42a.jpg	Edgar Link	pending
image_43a.jpg	Edgar Link	pending
image_44a.jpg	Edgar Link	pending
image_45a.jpg	Edgar Link	pending
image_46a.jpg	Edgar Link	pending
image_47a.jpg	Edgar Link	pending
image_48a.jpg	Edgar Link	pending
image_49a.jpg	Edgar Link	pending
image_4a.jpg	Edgar Link	pending
image_50a.jpg	Edgar Link	pending
image_51a.jpg	Edgar Link	pending
image_52a.jpg	Edgar Link	pending
image_53a.jpg	Edgar Link	pending
image_54a.jpg	Edgar Link	pending
image_55a.jpg	Edgar Link	pending
image_56a.jpg	Edgar Link	pending
image_57a.jpg	Edgar Link	pending
image_58a.jpg	Edgar Link	pending
image_59a.jpg	Edgar Link	pending
image_5a.jpg	Edgar Link	pending
image_60a.jpg	Edgar Link	pending
image_61a.jpg	Edgar Link	pending
image_62a.jpg	Edgar Link	pending
image_63a.jpg	Edgar Link	pending
image_64a.jpg	Edgar Link	pending
image_65a.jpg	Edgar Link	pending
image_66a.jpg	Edgar Link	pending
image_67a.jpg	Edgar Link	pending
image_68a.jpg	Edgar Link	pending
image_69a.jpg	Edgar Link	pending
image_6a.jpg	Edgar Link	pending
image_70a.jpg	Edgar Link	pending
image_71a.jpg	Edgar Link	pending
image_72a.jpg	Edgar Link	pending
image_73a.jpg	Edgar Link	pending
image_74a.jpg	Edgar Link	pending
image_75a.jpg	Edgar Link	pending
image_76a.jpg	Edgar Link	pending
image_77a.jpg	Edgar Link	pending
image_78.jpg	Edgar Link	pending
image_7a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2022 Q4 Form 10-Q Financial Statement

#000082787122000027 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2022 Q4 Form 10-Q Financial Statement

#000082787122000027 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx